Drug discovery and development for neuropsychiatric and neurodegenerative disorders
Drug Discovery and Development for Neuropsychiatric Disorders
The laboratory is on track to an Investigational New Drug (IND) Application regarding novel drug(s) that target brain serotonin receptors for treatment of neuropsychiatric disorders, including, autism spectrum disorder, obsessive-compulsive disorders (binge eating, attention deficit-hyperactivity disorder [ADHD], addiction) and diseases involving cognition impairment (schizophrenia, dementias, psychoses). Development will proceed under the auspices of the National Institutes of Health (NIH) and Boston-based pharmaceutical industry partners, including the Northeastern start-up biotech, Seropeutics (https://www.northeastern.edu/cri/spinouts/seropeutics/).
In addition to structure-based design and synthesis of new chemical entities, laboratory drug discovery and development technology includes computational chemistry and molecular modeling, molecular neuropharmacology, pharmacokinetics, and preclinical in vivo behavioral methodologies for development of drug candidates to treat neuropsychiatric disorders.